(NASDAQ: PALI) Palisade Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.67%.
Palisade Bio's earnings in 2026 is -$11,226,000.On average, 7 Wall Street analysts forecast PALI's earnings for 2026 to be -$69,211,991, with the lowest PALI earnings forecast at -$178,148,238, and the highest PALI earnings forecast at -$25,032,539. On average, 6 Wall Street analysts forecast PALI's earnings for 2027 to be -$83,978,209, with the lowest PALI earnings forecast at -$178,148,238, and the highest PALI earnings forecast at -$26,597,073.
In 2028, PALI is forecast to generate -$54,713,979 in earnings, with the lowest earnings forecast at -$110,977,591 and the highest earnings forecast at -$18,774,404.